Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

 

Reality Check on Type 2 Diabetes (SGLT2 and Combo) 

Market access for type 2 Diabetes (SGLT2 and Combo) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, almost 47% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In January 2020, the FDA approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) to lower blood sugar in adults with type 2 diabetes, along with diet and exercise. The drug is marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Co., and it is the first triple combination product in the indication
  • Key Findings: Coverage for the drugs is via the pharmacy benefit. Overall the agents in this indication enjoy widespread coverage by a majority of payers. Most patients will have numerous options to choose from depending on their formulary, though which agents are considered preferred will depend on contracts and rebates

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.

MMIT-RC_Thumbnail_1-1.png